Navidea Biopharmaceuticals Receivables

Navidea Biopharmaceuticals (NAVB) currently reports a receivables of $31K as of September 2023. That compares with $160K in the prior-year period — down 80.1% year over year. Use the charts on this page to explore Navidea Biopharmaceuticals's receivables history and peer comparisons.

Navidea Biopharmaceuticals's receivables decreased from $160K to $31K — a 80.1% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Navidea Biopharmaceuticals reported $31K in receivables as of September 2023. That compares with $160K in the prior-year period — down 80.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $31K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Navidea Biopharmaceuticals, and consider following NAVB for alerts when major investors trade the stock.

Navidea Biopharmaceuticals is classified in the Healthcare sector. On receivables, it currently shows $31K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NAVB with unrelated industries.